Genomica Corporation and Celera Genomics Finalize Strategic Alliance.Business Editors & Health/Medical Writers BIOWIRE2K BOULDER, Colo.--(BW HealthWire)--April 30, 2001 Genomica Corporation (Nasdaq:GNOM): Genomica's Discovery Manager(TM) Celera Edition to Integrate With Celera's SNP SNP Scottish National Party Noun 1. SNP - (genetics) genetic variation in a DNA sequence that occurs when a single nucleotide in a genome is altered; SNPs are usually considered to be point mutations that have been evolutionarily Reference Database Genomica Corporation (Nasdaq:GNOM), a leading developer of software products that facilitate drug discovery and development, today announced it has signed an agreement finalizing the terms of a strategic alliance with Celera Genomics (NYSE NYSE See: New York Stock Exchange :CRA See Community Reinvestment Act. ), an Applera Corporation business. Under the terms of the contract, Genomica will create a special "Celera Edition" of its Discovery Manager genetic analysis software suite to integrate seamlessly with the SNP Reference Database module of the Celera Discovery System. Financial terms of the agreement were not disclosed. Celera's on-line SNP Reference Database is a comprehensive and integrated source of single nucleotide polymorphisms Noun 1. single nucleotide polymorphism - (genetics) genetic variation in a DNA sequence that occurs when a single nucleotide in a genome is altered; SNPs are usually considered to be point mutations that have been evolutionarily successful enough to recur in a (SNPs), the major form of DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. variation responsible for human traits, certain illnesses, and variable drug safety and efficacy. Under the terms of the alliance, authorized Celera customers will be able to load SNP data into Genomica's Discovery Manager for local data management and analysis using Discovery Manager's powerful toolset. From within Discovery Manager, users will be able to navigate directly to the Celera Discovery System to create detailed, web-based SNP reports. "This alliance brings together the leaders in genetic data content and data analysis to provide biopharmaceutical companies with an unmatched solution for studying human genetic variation," said Genomica CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Teresa Ayers. "Genetic variation data is increasingly valuable and fundamental in all phases of the drug discovery, development, and delivery process. Our partnership with Celera represents a key element of our strategy to provide our bioinformatics technology across the continuum of drug discovery and development, whenever genetic variation matters. This relationship, along with our partnership with Celera's sister company, Applied Biosystems Applied Biosystems, Inc. (formerly NASDAQ: ABIO) is the original name of a pioneer biotechnology company founded in 1981 in Foster City, California, among the Silicon Valley cities of the southern San Francisco Bay Area. , the market leader in genotyping Genotyping refers to the process of determining the genotype of an individual with a biological assay. Current methods of doing this include PCR, DNA sequencing, and hybridization to DNA microarrays or beads. instruments, affirms Genomica's role in setting the standard for genetic analysis." "This agreement with Genomica gives researchers an advantage in gathering, organizing and analyzing SNP data," said James Peck There are several people named James Peck:
The Genomica-Celera alliance benefits researchers by providing a tested, fully integrated solution that allows customers of both companies to use Genomica's flexible, analytical tools together with Celera's comprehensive SNP data. This combined solution allows researchers to select SNP markers of interest from Celera's reference SNP database and store them locally in Discovery Manager for efficient data management and analysis, while full Celera SNP reports are only a mouse click away. About Genomica Corporation Genomica Corporation (Nasdaq:GNOM) develops and markets innovative software products and services that enable pharmaceutical and biotechnology researchers to accelerate the drug discovery and development process. Genomica's customers include leading genomics-based research organizations such as AstraZeneca, GlaxoSmithKline, Aventis, Pfizer, and the National Cancer Institute. Genomica is also collaborating with Applied Biosystems to develop software products to be used with AB's industry-leading hardware for drug discovery. For additional information on Genomica, please visit its website, at www.genomica.com. Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "believe," "expect," "intend," "anticipate," "should," "planned," "estimated," and "potential," among others. These forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. are based on Genomica Corporation's current expectations. The Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 provides a "safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " for such forward-looking statements. In order to comply with the terms of the safe harbor, Genomica Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Such factors include, but are not limited to, Genomica's reliance on key personnel, risks as related to market acceptance of Genomica's product, rapid technological change in Genomica's market, potential defects associated with Genomica's product, Genomica's need to maintain and enhance strategic relationships with larger companies, activities by Genomica and others regarding protection of intellectual property, release of competitive products and other actions by competitors, and economic downturns in either domestic or foreign markets. Further details on these risks and other risks are set forth in Genomica's filings with the Securities and Exchange Commission. These filings are available on a website maintained by the Securities and Exchange Commission on the World Wide Web at www.sec.gov. Genomica does not undertake an obligation to update forward-looking statements. Genomica and Discovery Manager are trademarks or registered trademarks of Genomica Corporation in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. and in other countries. Applera, Applied Biosystems, Celera, Discovery System, and SNP Reference Database are trademarks of their respective owners. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion